Tag: peptide receptor radionuclide therapy

Dr. Satya (Nanu) Das to Be Featured Guest for CCF’s Luncheon with the Experts

Satya (Nanu) Das, MD, MSCI, medical oncologist and hematologist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, will be the featured guest for Facebook Live Luncheon with the Experts on Thursday, January 27, 2022 from 12 noon to 1 pm, Eastern…

News and Notes from the Carcinoid Cancer Foundation, October 2021

Congratulations to NET expert Pamela Kunz, MD, who was named Woman Oncologist of the Year! Dr. Kunz is Associate Professor of Medicine (Medical Oncology), Director of the Center for Gastrointestinal…

Dr. Nancy Sharma to be Featured Guest for Luncheon with the Experts

Nancy Sharma, MD, medical oncologist and hematologist at Swedish Cancer Institute in Issaquah, Washington, will be the featured guest for CCF’s Facebook Live Luncheon with the Experts on Thursday, May 20 from 12 noon to 1 pm, Eastern Time.

Growing up …

Dr. Lale Kostakoglu-Shields to Be Featured Guest for Luncheon with the Experts

Lale Kostakoglu-Shields, MD, MPH, a nuclear medicine expert, will be the featured guest for CCF’s Luncheon with the Experts on Thursday, April 15, 2021 from 12 noon to 1 pm, Eastern Time. Dr. Kostakoglu-Shields is a professor of radiology and medical…

Peptide Receptor Radionuclide Therapy, PRRT: Updates and Locations

Since we shared the news of the FDA’s January 26, 2018 approval of peptide receptor radionuclide therapy, PRRT, with Lutathera  (lutetium Lu 177 dotatate), more information has become available for the neuroendocrine tumor community, including updates…

PRRT – FDA Approves Lutathera®, What’s Next?

The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community.  It has also raised a host of questions including:

• What exactly is this

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017.  Additionally, an Expanded…

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, March 2016

Breaking News from Advanced Accelerator Applications (AAA) about PRRT Treatment— Advanced Accelerator Applications announced on March 23 that the company has initiated an expanded access program (EAP) in the United States for the investigational…

Neuroendocrine Tumors to Be Focus of Presentations and Posters at ASCO Gastrointestinal Cancers Symposium

Presentations on recent advances in the treatment of neuroendocrine tumors (NETs) and new findings from the NETTER-1 clinical study on PRRT with Lutathera along with posters on a wide variety of subjects about NETs will be part of the program during the…

Neuroendocrine Tumors Focus of Upcoming Issue of Hematology/Oncology Clinics

Neuroendocrine Tumors will be featured in the February 2016 issue of Hematology/Oncology Clinics. Dr. Jennifer Chan and Dr. Matthew Kulke, both from Dana-Farber Cancer Institute in Boston, Massachusetts are Editors of the issue, published by Elsevier.…